Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies (“Theranostics”) to target cancer first at the “diagnosis” phase and then at the “therapy” phase, using the same biological targets (“see to treat”).
Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus
Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection
October 16, 2024